Indexed in

External link

License and use

Citations

Altmetrics

Analysis of institutional authors

Domenech GAuthorArroyo VAuthorFernandez Gomez, JavierAuthor

Share

Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on-chronic liver failure

Publicated to:Journal Of Hepatology. 79 (1): 79-92 - 2023-07-01 79(1), DOI: 10.1016/j.jhep.2023.03.013

Authors: Agarwal, B; Cañizares, RB; Saliba, F; Ballester, MP; Tomescu, DR; Martin, D; Stadlbauer, V; Wright, G; Sheikh, M; Morgan, C; Alzola, C; Lavin, P; Green, D; Kumar, R; Sacleux, SC; Schilcher, G; Koball, S; Tudor, A; Minten, J; Domenech, G; Aragones, JJ; Oettl, K; Paar, M; Waterstradt, K; Bode-Boger, SM; Ibáñez-Samaniego, L; Gander, A; Ramos, C; Chivu, A; Stange, J; Lamprecht, G; Sanchez, M; Mookerjee, RP; Davenport, A; Davies, N; Pavesi, M; Andreola, F; Albillos, A; Cordingley, J; Schmidt, H; Carbonell-Asins, JA; Arroyo, V; Fernandez, J; Mitzner, S; Jalan, R

Affiliations

Abstract

Background & Aims: Acute-on-chronic liver failure (ACLF) is characterized by severe systemic inflammation, multi-organ failure and high mortality rates. Its treatment is an urgent unmet need. DIALIVE is a novel liver dialysis device that aims to exchange dysfunctional albumin and remove damage-and pathogen-associated molecular patterns. This first-in-man randomized -controlled trial was performed with the primary aim of assessing the safety of DIALIVE in patients with ACLF, with secondary aims of evaluating its clinical effects, device performance and effect on pathophysiologically relevant biomarkers.Methods: Thirty-two patients with alcohol-related ACLF were included. Patients were treated with DIALIVE for up to 5 days and end points were assessed at Day 10. Safety was assessed in all patients (n = 32). The secondary aims were assessed in a pre -specified subgroup that had at least three treatment sessions with DIALIVE (n = 30). Results: There were no significant differences in 28-day mortality or occurrence of serious adverse events between the groups. Significant reduction in the severity of endotoxemia and improvement in albumin function was observed in the DIALIVE group, which translated into a significant reduction in the CLIF-C (Chronic Liver Failure consortium) organ failure (p = 0.018) and CLIF-C ACLF scores (p = 0.042) at Day 10. Time to resolution of ACLF was significantly faster in DIALIVE group (p = 0.036). Biomarkers of systemic inflammation such as IL-8 (p = 0.006), cell death [cytokeratin-18: M30 (p = 0.005) and M65 (p = 0.029)], endothelial function [asymmetric dimethylarginine (p = 0.002)] and, ligands for Toll-like receptor 4 (p = 0.030) and inflammasome (p = 0.002) improved significantly in the DIALIVE group.Conclusions: These data indicate that DIALIVE appears to be safe and impacts positively on prognostic scores and patho-physiologically relevant biomarkers in patients with ACLF. Larger, adequately powered studies are warranted to further confirm its safety and efficacy.Clinical trial number: NCT03065699.& COPY; 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords